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Abstract
Autism spectrum disorder (ASD) symptoms frequently occur in subjects with attention deficit/hyperactivity disorder
(ADHD). While there is evidence that both ADHD and ASD have differential structural correlates, no study to date has
investigated these structural correlates within a framework that robustly accounts for the phenotypic overlap between the
two disorders. The presence of ASD symptoms was measured by the parent-reported Children’s Social and Behavioural
Questionnaire (CSBQ) in ADHD subjects (n = 180), their unaffected siblings (n = 118) and healthy controls (n = 146). ADHD
symptoms were assessed by a structured interview (K-SADS-PL) and the Conners’ ADHD questionnaires. Whole brain T1-
weighted MPRAGE images were acquired and the structural MRI correlates of ASD symptom scores were analysed by
modelling ASD symptom scores against white matter (WM) and grey matter (GM) volumes using mixed effects models
which controlled for ADHD symptom levels. ASD symptoms were significantly elevated in ADHD subjects relative to both
controls and unaffected siblings. ASD scores were predicted by the interaction between WM and GM volumes. Increasing
ASD score was associated with greater GM volume. Equivocal results from previous structural studies in ADHD and ASD may
be due to the fact that comorbidity has not been taken into account in studies to date. The current findings stress the need
to account for issues of ASD comorbidity in ADHD.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) and autism
spectrum disorder (ASD) are both severely impairing, highly
heritable neurodevelopmental disorders [1,2]. ASD is charac-
terised by impaired social and communicative skills as well as
restricted and repetitive behaviours and interests, whereas ADHD
is characterised by severe inattention and/or hyperactivity and
impulsivity [3]. Both disorders frequently co-occur with estimates
for the presence of ADHD within ASD ranging from 30% to 80%,
while the presence of ASD in ADHD is estimated at 20% to 50%
[1], [2,4–6]. Deficits in executive function and motor speed have
been linked to familial vulnerability for both ASD and ADHD [7–
9]. Studies have also documented an overlap of genetic factors that
relate to both ASD and ADHD [4]. Overall, these findings suggest
that there are shared etiological pathways for ASD and ADHD
which need to be studied in more detail.
Quantitative measures that reflect the severity of ASD and
ADHD symptoms may be useful to characterise both disorders in
terms of a continuous distribution in which clinical disorders
represent extreme variants of typical behaviour [10,11]. Studies
investigating the continuous distribution of both disorders as well
as their overlap, as opposed to an exclusive focus on a categorical
diagnosis, may be a fruitful direction for future research [10]. Such
an approach may help to better characterise the heterogeneous
nature of these disorders as well as the extent to which they
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e101130
overlap [12]. Previously, ASD symptoms have been found to be
different in various groupings of ADHD classes, with the class
having the most severe ADHD symptoms also having the most
severe ASD symptoms [13]. In typically developing people, recent
work has found brain regions that are commonly as well as
uniquely correlated with ASD and ADHD symptom severity [14].
GM volume in the left inferior frontal gyrus was found to be
correlated with symptom severity in both disorders [14]. Volu-
metric changes in the left posterior cingulate were found to be
specific to ASD, while ADHD symptom severity was found to be
specifically correlated with the right parietal lobe, right temporal
frontal cortex, bilateral thalamus and left hippocampus/amygdala
complex [14]. The study by Geurts et al. indicates that ASD and
ADHD form a continuum extending into the general population.
However, the conclusions were complicated by the fact that the
directions of the brain-behaviour relationships were not consistent
for all regions compared to clinical studies [14].
Brain volume abnormalities are important indicators of
pathophysiological processes that likely reflect disorder etiology.
A number of meta-analyses have found reduced brain volume in
ADHD in the majority of studies investigated (with ages ranging
from ,10–37 years of age) [15], [16,17]. Regional volume
reductions in ADHD subjects were robustly localised to the globus
pallidus, putamen, caudate nucleus and lentiform gyrus [15],
[16,17]. Total brain volume and grey matter volume have both
been found to be decreased in ADHD compared with typically
developing controls [15,18] [19,20]. However, both increasing age
and stimulant medication were also found to be independently
associated with more normal GM volumes.
It is of note that the profile of changes in brain volume in ASD is
different from that of ADHD, with findings suggesting that the
brain undergoes a period of accelerated growth in the first four
years of life before reaching a plateau within a normal range by
adolescence, which in turn is followed by volume decline in
adulthood relative to typically developing controls [21], [22–27].
Importantly, in young children with autism (2–3 years old) WM
enlargement has been shown to be greater than GM enlargement
(18% more cerebral and 38% more cerebellar WM) [28]. This
WM enlargement in young children was then found to be reversed
in 12–16 year old children with autism, with WM volume reduced
relative to controls [28]. In older individuals with autism, voxel-
based methods have also shown less WM intensity than in age-
matched controls [29,30]. However, a more recent meta-analysis
has indicated consistent increases in WM volume in the right
arcuate fasciculus and left inferior frontoocciptal and uncinate
fasciculi in adults as well as in children and adolescents with ASD
[31].
For GM, several studies in adolescents and adults with ASD
have reported a 6–12% increase in GM volume relative to controls
[32] [31,33,34]. A meta-analysis indicated a small increase in GM
volume in the left middle and inferior frontal gyri in ASD [33].
The same meta-analysis also indicated robust reductions in GM in
the amgydala-hippocampus complex and medical parietal regions
[33]. Overall, the GM findings were found to be more pronounced
in adults, but the only statistically significant difference was a
greater GM volume reduction in the precuneus in adult compared
with adolescent samples [33]. However it is difficult to disentangle
whether these effects are due to developmental processes or are
secondary to the effects of living with cognitive differences.
Significant age-related improvements in ASD have been
documented in adolescents and adults [35]. This also suggests
that a selection bias exists in current studies, with older
participants possibly having more severe symptoms and thus
more likely to have prominent GM abnormalities.
For ADHD, the ontogenetic onset of smaller brain size is not
known, but there is some evidence that smaller brain volumes in
ADHD persist to the end of adolescence [18]. However, this
phenomenon may attenuate in adulthood, with studies noting
normal brain size in adults with ADHD [36]. In summary, the
most abnormal volumes in ASD generally occur in early
childhood, while the most abnormal volumes in ADHD occur in
middle to late childhood [15,37,38].
Therefore, while there is evidence that both ADHD and ASD
have specific and differential structural correlates, no study to date
has investigated these structural correlates within a framework that
robustly accounts for the phenotypic overlap between the two
disorders. Only one study to date has directly compared brain
volumes in ASD and ADHD [39]. The age of all subjects ranged
from 10 to 16 years, and no differences were found between the
two disorders in terms of total GM and WM volumes [39]
Additionally, no differences were found between either disorder
and typically developing controls [39]. The relatively small size of
the cohort (15 ASD subjects, 15 ADHD subjects, 15 controls) may
have contributed to the negative findings.
The present study was based on the premise that the extent to
which ASD symptoms occur in ADHD may have a pronounced
effect on the profile of structural brain volumes in ADHD. Thus,
MRI volumetric correlates of ASD symptoms in a large sample of
ADHD probands, their unaffected siblings, as well as healthy
controls were investigated. Mixed effects models, which controlled
for ADHD symptom levels in the random effects structure of the
model, were used to assess the relationship between global WM,
GM and autism spectrum symptoms. As previous studies have
found raised GM volume [32] in adolescent ASD subjects, we
hypothesized that this profile would also be present in ADHD
subjects with elevated autistic spectrum symptoms.
Methods
Participants
The study was approved by the Radboud University Medical
Centre Research Ethics Committee and was in accordance with
the Declaration of Helsinki. All participants over 18 years of age
provided informed written consent. For participants under 18
years of age, informed written consent was obtained from the next
of kin, caretakers, or guardians on behalf of the participants. This
procedure was approved by the Radboud University Medical
Centre Research Ethics Committee.
Participants were part of the NeuroIMAGE study. This is a
prospective longitudinal MRI study (2009–2012) of the Dutch
subsample of the International Multicenter ADHD Genetics
(IMAGE) study performed between 2003–2006 [40–42]. All
members of ADHD and control families were invited for follow-
up measurement, with a mean follow-up period of 5.9 years
(SD= .72). For the present analyses, subjects were selected from
the total data set (n = 1084) when the following data was available:
a high quality T1-weighted MPRAGE image, complete informa-
tion from the Children’s Social and Behavioural Questionnaire
(that provides information on the autism spectrum symptoms),
complete information from the Schedule for Affective Disorders
and Schizophrenia for School-Age Children - Present and Lifetime
Version (K-SADS-PL) [43] and the Conners ADHD question-
naire. IQ information and medication history were also required
in order to include subjects in the current study. Subjects with a
sub-threshold ADHD diagnosis (n = 75), i.e. those with signifi-
cantly elevated ADHD symptoms but failed to meet the clinical
criteria for a diagnosis of ADHD were excluded. Subjects were
also excluded if there was inconsistency between the ADHD
ASD Spectrum Traits in ADHD
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Figure 1. ASD symptoms in healthy controls, unaffected siblings and ADHD. ADHD subjects were found to have significantly higher scores
relative to both unaffected siblings and healthy controls. ***p,0.001, with post-hoc Tukey test, following an ANOVA. ASD symptom score refers to an
aggregate score from the four Children’s Social and Behavioural Questionnaire (CSBQ) subscales, (1) social interest, (2) social understanding, (3)
stereotypy and (4) resistance to change. Abbreviations: con, Control; unaf sib, Unaffected Siblings, adhd, Attention Deficit Hyperactivity Disorder.
doi:10.1371/journal.pone.0101130.g001
Table 2. Final, generalised mixed-effect model showing fixed effects for ASD score modelled against white matter residual and
grey matter volumes.
Fixed Effects Estimate Standard Error t-value p-value
WM resid 20.485 0.206 22.354 0.019
GM 0.013 0.013 0.994 0.321
Unaff. Sib. 20.538 3.652 20.147 0.883
ADHD 21.056 3.815 5.519 0.000
Age 0.071 0.177 0.398 0.691
Male 1.847 0.674 2.740 0.006
WM resid6GM 0.001 0.000 2.199 0.028
Unaff. Sib6Age 0.059 0.211 0.279 0.781
ADHD6Age 20.675 0.207 23.264 0.001
Formula:
ASD symptoms*WM resid  GMzDiagnosis  AgezGenderz
1DTotal ADHD symptomsð Þz
1DFamilyð Þz
1DIQð Þz
1DADHD medicationð Þz
1DScanner typeð Þ
;
‘‘,’’ means modelled against, and ‘‘(1| factor)’’ means that a factor is included as a random effect.
A generalised mixed-effect model is run using normalised volumes of grey and white matter as explanatory variables together with age as a random effect. ASD score is
set as the response variable. The final model is derived following an iterative model selection procedure that involves comparing successive models using Akaike’s
Information Criterion (see Methods for detailed description of model selection procedure). ASD score refers to an aggregate score from the four Children’s Social and
Behavioural Questionnaire (CSBQ) subscales, (1) social interest, (2) social understanding, (3) stereotypy and (4) resistance to change.
Abbreviations: WM, normalised WM volume; GM, normalised GM volume; US, unaffected siblings; WM:GM, WM by GM interaction; US: Age, unaffected sibling by Age
interaction; ADHD:Age, ADHD by Age interaction.
doi:10.1371/journal.pone.0101130.t002
ASD Spectrum Traits in ADHD
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Table 3. Final, generalised mixed-effect model showing random effects for ASD score modelled against white matter residual and
grey matter volumes.
Random Effects Variance S.D.
Family Relatedness 8.765 2.961
IQ 1.098 1.048
Total ADHD Score 5.474 2.340
ADHD medication 0.000 0.000
Scanner Type 0.000 0.000
Formula:
ASD symptoms*WM resid  GMzDiagnosis  AgezGenderz
1DTotal ADHD symptomsð Þz
1DFamilyð Þz
1DIQð Þz
1DADHD medicationð Þz
1DScanner typeð Þ
;
‘‘,’’ means modelled against, and ‘‘(1| factor)’’ means that a factor is included as a random effect.
A generalised mixed-effect model is run using normalised volumes of grey and white matter as explanatory variables together with age as a random effect. ASD score is
set as the response variable. The final model is derived following an iterative model selection procedure that involves comparing successive models using Akaike’s
Information Criterion (see Methods for detailed description of model selection procedure). ASD score refers to an aggregate score from the four Children’s Social and
Behavioural Questionnaire (CSBQ) subscales, (1) social interest, (2) social understanding, (3) stereotypy and (4) resistance to change.
Abbreviations: WM, normalised WM volume; GM, normalised GM volume; US, unaffected siblings; WM:GM, WM by GM interaction; US: Age, unaffected sibling by Age
interaction; ADHD:Age, ADHD by Age interaction.
doi:10.1371/journal.pone.0101130.t003
Figure 2. ASD scores are significantly positively correlated with total grey matter volume. The volumes of grey and white matter are
normalised for total intracranial volume. A regression line is plotted where the Pearson’s product-moment correlation is significant with p,0.05. ASD
symptom score refers to an aggregate score from the four Children’s Social and Behavioural Questionnaire (CSBQ) subscales, (1) social interest, (2)
social understanding, (3) stereotypy and (4) resistance to change. Abbreviations: con, Control; unaf sib, Unaffected Siblings, adhd, Attention Deficit
Hyperactivity Disorder; ASD, autism spectrum disorder.
doi:10.1371/journal.pone.0101130.g002
ASD Spectrum Traits in ADHD
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diagnosis derived from the different questionnaires employed
(n = 53). The resulting data set was then age- and gender-matched;
so that the current study included 90 male and 90 female ADHD
subjects, 62 male and 62 female unaffected siblings of ADHD
subjects and 70 male and 70 female healthy control children. The
age range of participants was 7.4 to 28.5 years. All participants
were of European Caucasian descent and had an IQ$70.
Demographic characteristics of each subject group are provided
in Table 1. Subjects who were taking ADHD medication stopped
medication (both stimulant and non-stimulant) for 48 hours prior
to scanning. Regarding medication history, 71 ADHD subjects
(39%) were not currently taking ADHD medication, 93 ADHD
subjects (52%) were taking one ADHD medication, and 16
ADHD subjects (9%) were currently taking two ADHD medica-
tions. A complete overview of medication is provided in Table S1.
ADHD diagnosis and symptom measures
All participants were assessed using a semi-structured diagnostic
interview (Dutch translation of the Schedule for Affective
Disorders and Schizophrenia for School-Age Children - Present
and Lifetime Version (K-SADS-PL) [43] and Conners’ ADHD
questionnaire to determine ADHD diagnoses. Each child was
assessed with a parent-rated questionnaire (Conners’ Parent
Rating Scale – Revised: Long version (CPRS-R:L) combined
with either a teacher-rating (Conners’ Teacher Rating Scale –
Revised: Long version (CTRS-R:L) applied for children,18 years
or a self-report Conners’ Adult ADHD Rating Scales – Self-
Report: Long version (CAARS-S:L) applied for children $18
years. A diagnostic algorithm was applied to combine symptom
counts on the K-SADS-PL and Conners’ questionnaires. A
detailed description of the diagnostic algorithm is provided in
the supplementary information (Diagnostic Algorithm S1). This
algorithm was used to diagnose subjects and also to provide a
continuous score for an overall level of ADHD symptoms that
combines both inattentive and hyperactive symptoms. While ASD
symptoms were present in the cohort and were significantly
elevated in the ADHD group (see Results), a clinical diagnosis of
autism or Asperger’s syndrome had been an exclusion criterion in
the original IMAGE study.
ASD measures
The Children’s Social and Behavioural Questionnaire (CSBQ)
[44] was used in the current study as it can measure the
continuous distribution of autistic symptoms in the general
population as well as in clinical groups outside of autism, including
ADHD [44,45]. Most instruments for ASD are designed to assess
clinical cases and are not suitable for assessing milder ASD
symptoms. The CSBQ was originally developed because existing
instruments did not capture more subtle social problems found in
the milder end of the autism spectrum [44]. The CSBQ has
Figure 3. ASD score contour graph for the interaction between WM, GM and ASD scores. The best mixed effects model was converted
into a function in R which allowed ASD scores to be extrapolated for a range of GM and WM volumes (see Methods for full description). The best
mixed effects model included GM and WM residual terms (see Methods). Volumes are normalised for total intracranial volume. ASD score refers to an
aggregate score from the four Children’s Social and Behavioural Questionnaire (CSBQ) subscales, (1) social interest, (2) social understanding, (3)
stereotypy and (4) resistance to change.
doi:10.1371/journal.pone.0101130.g003
ASD Spectrum Traits in ADHD
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previously been shown to be valuable in measuring subthreshold
autistic symptoms [44–49,40]. In the current study, where clinical
ASD was an exclusion criterion, but where milder autistic
symptoms are expected to be elevated in the ADHD group
[2,4–6,50], the CSBQ is ideally suited for the purpose of the study.
The CSBQ contains 49 items on a 3-point Likert scale. It
contains items that refer directly to the DSM-IV criteria for
autism, but it also captures more subtle symptoms of ASD.
Therefore, it is suitable for measuring behavioural problems as
seen in children with milder variants of ASD. CSBQ items are
grouped into the following six subscales: (1) tuned, (2) social
interest, (3) orientation, (4) social understanding, (5) resistance to
change, and (6) stereotypy. It was administered in the parent-
report form.
All items contained within each subscale are found in the
supplemental information (Questionnaire Items S1). The CSBQ
has good internal, test-retest, and inter-rater reliability, and
demonstrated convergent and divergent validity [44]. The CSBQ
appears to differentiate between autism and pervasive develop-
mental disorders - not otherwise specified (PDD-NOS), and can
also differentiate between PDD-NOS and ADHD [44,51].
Additionally, to assess the content validity of the CSBQ, it has
previously been compared to an autism screening instrument, the
Autism Behavior Checklist (ABC) [52]. A strong correlation of
0.75 was found between the total scores of both questionnaires in a
large Dutch population sample [45]. The CSBQ has also been
compared with the Autism Diagnostic Interview-Revised (ADI-R),
Autism Diagnostic Observation Schedule (ADOS), and clinical
classification in children with mild and moderate intellectual
disability [53]. In that study, the contribution of the CSBQ to a
classification of ASD was most specific for the ‘‘social’’ and
‘‘stereotypy’’ subscales, with high coherence with all three
classification methods [53].
An aggregate score from the four subscales, (1) social interest, (2)
social understanding, (3) stereotypy and (4) resistance to change,
was used in the current study to capture the core symptoms of
ASD. This aggregate score has been successfully used to selectively
probe ASD symptoms in previous studies [47,54]. The remaining
two CSBQ subscales (tuned and orientation) probe dysfunctional
social behaviours which, although characteristic for ASD, are also
related to the ADHD dimensions of hyperactivity/impulsivity and
attention problems, respectively [44], and were not considered in
the current study for this reason.
High Resolution T1W Structural Image Acquisition and
Processing
Whole brain T1 weighted MPRAGE images were acquired at
1.5T using a product 8 channel phased array headcoil on a
Siemens Sonata scanner at the Free University in Amsterdam and
a 1.5T Siemens Avanto MR scanner at the Donders Institute for
Brain, Cognition and Behaviour in Nijmegen. A breakdown of the
distribution of subjects scanned at the two sites is included in Table
S2. TI/TE/TR = 1000/2.95/2730 ms, imaging matrix 2566256,
176 slices, voxel size 16161 mm3, GRAPPA acceleration 2. Brain
tissue probability maps for white matter (WM), grey matter (GM)
and cerebrospinal fluid (CSF) were estimated using the unified
Figure 4. ASD scores decrease significantly with age within the ADHD groups. A regression line is plotted where the Pearson’s product-
moment correlation is significant with p,0.05. ASD score refers to an aggregate score from the four Children’s Social and Behavioural Questionnaire
(CSBQ) subscales, (1) social interest, (2) social understanding, (3) stereotypy and (4) resistance to change. Abbreviations: con, Control; unaf sib,
Unaffected Siblings, ADHD, Attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder.
doi:10.1371/journal.pone.0101130.g004
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segmentation algorithm as implemented in the VBM8 toolbox of
SPM8 [55]. Total GM, WM and CSF volumes were computed by
voxelwise summation of their probability maps. Total intracranial
volume (ICV) was then computed as the sum of WM, GM and
CSF volume.
The following formula was used to compute normalised
volumes of global GM and WM:
total volume of GM (mm3)/ICV (mm3)61000.
total volume of WM (mm3)/ICV (mm3)61000.
Statistics
As ASD scores are influenced by a range of factors, mixed-
effects models allow us to consider factors that potentially
contribute to the understanding of the data (i.e. fixed factors),
while controlling for additional factors associated with the subjects
(i.e. random factors).
R statistical software (Version 2.15.1) [56], including the lme4
package [57] was used for all statistical analyses. In the current
study, the ‘‘glmer’’ function [57] was used to fit a generalised
mixed-effects model using maximum likelihood (ML). As our
objective was to determine the extent to which the ASD score is
influenced by the diagnosis group (i.e. control, unaffected sibling
or ADHD), GM and WM, these three factors were set as fixed
effects. Age was also set as a fixed factor. The total ADHD
symptom score was set as a random effect, in order to control for
differences in ADHD symptoms between participants, thus
allowing us to focus specifically on the ASD score. IQ, ADHD
medication, scanner type and family relatedness were also set as
random effects. The response variable was set as ASD score,
calculated as an aggregate of the four CSBQ subscales (‘social
interest’, ‘social understanding’, ‘stereotypy’ and ‘resistance to
change’) that probe ASD.
Models were created using normalised WM and GM volumes.
Including both WM and GM variables allowed us to determine
not only the extent to which GM and WM drive changes in ASD
scores, but also the nature of the interactions between the
explanatory variables. WM and GM volumes were co-linear (i.e.
correlated with each other) and the models developed took this
into account by orthogonalizing these regressors relative to each
other to isolate the unique contribution of each explanatory
variable independent from what is shared between them. A WM
residual term was derived from the regression residuals when WM
was regressed against GM. This enabled us to use GM together
with a WM residual term (WM resid) in our mixed effect model. A
model using WM together with a GM residual term (GM resid)
was also created. Un-biased analyses and comparisons could then
be carried out based on the models.
The models were fitted by maximum likelihood estimation. The
starting model using GM resid and WM terms was:
ASD score*GM resid  WM  Diagnosis  Age  Genderz
1DADHD symptomsð Þz
1DScanner typeð Þz
1DIQð Þz
1DFamily relatednessð Þz
1DADHD medicationð Þ
where ‘‘,’’ means ‘‘modelled against’’; ‘‘(1| factor)’’ means that
factor is included as a random effect, and ‘‘Diagnosis’’ refers to the
three diagnostic groups, i.e. control, unaffected siblings and
ADHD. ‘‘*’’ means interacting with, and the model assesses
interactions among all terms, up to a 5-way interaction among all
fixed effects.
The starting model using GM and WM resid terms was:
ASD score*WM resid  GM  Diagnosis  Age  Genderz
1DADHD symptomsð Þz
1DScanner typeð Þz
1DIQð Þz
1DFamily relatednessð Þz
1DADHD medicationð Þ
We fit the full models as described above and then removed least
significant terms in an iterative process, checking for improved fit
according to Akaike’s Information Criterion (AIC) [58,59] until a
final model was obtained [60]. We have previously employed the
AIC tool for successful model selection in an MRI and structural
volume framework [61]. The models are thus primarily assessing
the influence of GM and WM on the ASD scores across all healthy
young controls, ADHD subjects and unaffected siblings (Sib) of
ADHD subjects.
To determine if the model using GM resid or the WM resid
term was a better predictor of ASD symptoms, the fits of the two
final models was compared using the ‘‘anova’’ function in R [60].
Contour Plots
The significant interaction between GM and WM was
visualized by means of a contour plot. Normalised WM and
GM volumes were used for creating this contour plot. ASD scores
were modelled as follows: model = lm (ASD score,GM*WM
resid); where ‘‘,’’ means modelled against, ‘‘*’’ means interacting
with, and, ‘‘lm’’ is used to fit a linear model in R. A matrix was
created for the WM and GM volumes, and the function was run
from the minimum to the maximum GM value within the matrix,
and also from the minimum to the maximum WM value within
the matrix. The contour plot enabled changes in ASD scores to be
visualised by means of a colour key with darker colours
representing lower ASD symptoms and lighter colours represent-
ing higher ASD symptoms.
Results
Demographic and Cognitive Characteristics
The demographic characteristics of the cohort are shown in
Table 1. ASD scores were significantly different between groups
[F(2,441) = 118, p,0.0001], with ADHD subjects having signifi-
cantly raised scores relative to both controls (p,0.0001) and
unaffected siblings (p,0.0001), while there was no significant
difference between controls and unaffected siblings (Fig. 1;
Table 1). ASD scores were found to be significantly positively
correlated with ADHD scores in control group (p = 0.046,
r = 0.165; Table S3) and in the ADHD group (p = 0.254,
r = 0.001; Table S3).
Mixed-effects models for ASD symptoms modelled
against global grey matter and white matter volumes
Following model simplification based on AIC, the optimal
model for ASD symptoms is shown in Table 2 and Table 3. This
model used the WM residual term together with GM (WM
resid:GM model) and was found to have a lower AIC value than
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the alternative model that used the GM residual term together
with the WM (GM resid:WM model). The alternative model is
also shown in Table S4.
For the fixed effects of the WM resid:GM model, the following
terms were significant: WM resid (p = 0.019); ADHD diagnosis
(p,0.0001); male gender (p = 0.006); WM resid6GM interaction
(p = 0.028); ADHD diagnosis6age (p = 0.001).
As the range of ASD scores in control and unaffected siblings is
limited, a mixed effect model was also developed based on the
inclusion of participants with an ASD score of 20 or higher. This
model also returned a significant WM resid6GM interaction
(p = 0.0029; Table S5).
The significant interaction between WM and GM was further
visualised with a scatter plot (Fig. 2) and a contour plot (Fig. 3). A
significant positive correlation was found between GM volume
and ASD scores for the ADHD group (p = 0.00025, r = 0.17)
(Fig. 2). No other significant correlation was found between GM
volume and ASD score for control or unaffected siblings. There
was also no significant correlation between WM volume and ASD
score for any of the groups examined. The best mixed effects
model (Table 2 and Table 3) was used to create a contour plot,
which further described the interaction between GM and WM.
The contour plot developed from the mixed effects model
indicates that the lowest ASD scores were found in areas of low
GM coupled with high WM (Fig. 3). Increasing ASD score was
accompanied by greater GM volume and lower WM volume up to
an ASD score on the CSBQ of ,10. For ASD scores greater than
,10, the volumetric profile indicated both raised GM and WM
volume (Fig. 3).
As there was a significant interaction found between the ADHD
diagnosis and age, this interaction was also visualised with a scatter
plot (Fig. 4). ADHD subjects were found to have a significant
negative correlation between age and ASD scores (p,0.0005;
r =20.26) while there was no correlation between age and ASD
scores for unaffected siblings or controls (Fig. 4).
Total Intracranial Volume in Low and High ASD
Conditions
Total intracranial volume was plotted for Control, Unaffected
Sibling, ADHD with low ASD and ADHD with high ASD scores
(Fig. 5). Low ASD score was defined as 20 or lower as per the
CSBQ ASD score. A high ASD score was defined as greater than
20. ADHD participants with low ASD scores were found to have
significantly lower total intracranial volumes than control subjects
(p,0.05). No other significant differences were found.
Discussion
In the current study, ASD symptoms as measured by the CSBQ
[44] were found to be significantly elevated in ADHD subjects
relative to both controls and unaffected siblings. These findings
agree with previous studies that have found elevated levels of ASD
symptoms in ADHD subjects [13,62]. There was a non-significant
increase in the ASD scores for unaffected siblings relative to
controls, which is in line with studies showing moderate increases
in ASD symptoms in unaffected siblings of ADHD subjects [40],
[63]. For ADHD subjects, the co-morbid ASD symptoms were
found to decrease significantly with age.
Structural MRI was used to investigate whether or not raised
ASD symptoms would be accompanied by a distinct anatomical
profile. When ASD scores were modelled against WM and GM
volumes using mixed-effects models that controlled for ADHD
symptom levels, a significant WM by GM interaction was found.
Investigation of the interaction between WM, GM and ASD
scores by means of a contour graph highlighted a specific
volumetric landscape with the lowest ASD scores found in areas
of low GM coupled with high WM. Increasing ASD scores were
accompanied by greater GM volumes and lower WM volumes.
While the GM profile constantly increased with greater ASD
scores, WM was found to decrease with greater ASD scores but for
the highest ASD scores WM volumes were also elevated.
The profile of increased GM volume in subjects with raised
ASD symptoms is in line with previous studies that have found
GM volume to be significantly increased in adolescent ASD
subjects [32]. Globally, decreased brain size has been the
predominant finding in ADHD [15,18], while ASD is generally
associated with brain overgrowth during infancy followed by a
return to normal total brain size in adolescence and possible
continued degeneration into middle age [64] [22–27]. Similarly,
although the majority of studies have found total brain volume to
be reduced in ADHD, some studies have reported no significant
differences in total brain volume between ADHD subjects and
typically developing controls [36,65–68]. These discrepancies may
be partly accounted for by the extent to which ASD symptoms are
present in the ADHD sample. The findings in the current paper
that ADHD with low ASD score had significantly reduced total
intracranial volume compared with control, whereas ADHD with
high ASD score showed no significant difference with control,
further emphasize the role that ASD symptoms may play in
influencing the landscape of brain volumetrics in ADHD subjects.
Meta-analyses suggest that increasing age and medication
treatment contribute to a degree of normalisation in brain volumes
in ADHD [16,17]. The current findings add to these studies by
indicating that ASD comorbidity may be an additional factor that
plays an important role in influencing brain volume in ADHD.
Decreased GM volume may be more pronounced when ASD
symptoms are absent or present only to a minor degree, as was the
case in the current study. Conversely, the current findings indicate
that elevated ASD symptoms are accompanied by raised GM
volume. The WM profile was more complex, with lower volumes
found as ASD scores increase, but higher volumes found for the most
extreme ASD scores. Previous studies have shown reduced WM
volume in adolescent and adult ASD subjects [28], [29,30], while
greater WM enlargement has been found in children with ASD [28].
A mixed effects model assessment, based on the same statistical
framework as the main analysis, but including only participants with
an ASD score of 20 or higher also revealed a significant GM by WM
interaction. This supplementary analysis indicates that those with
elevated ASD scores in the current cohort have a global volumetric
profile similar to that found in ASD studies.
The volumetric landscape for different ASD scores described by
the contour plot is not restricted to ADHD subjects but is also
applicable to unaffected siblings and healthy controls. No
significant interaction between GM, WM and ADHD was found,
nor were there significant interactions between GM, WM and
unaffected siblings, or between GM, WM and controls.
As ASD scores remained low in both controls and unaffected
siblings, their volumetric profiles were constrained to a conjunc-
tion of low GM coupled with high WM volume. Conversely, ASD
scores for ADHD subjects were more heterogeneous, with a
significantly higher mean, as well as greater variance and range.
Therefore, ADHD subjects exhibited a wide range of volumetric
profiles that were dependent on their ASD spectrum scores.
There was a significant age-related improvement in ASD
symptoms in ADHD subjects which is in agreement with previous
cross-sectional and longitudinal studies that have also found age-
related improvement in ASD [69,70] [71]. Neither WM nor GM
volume was found to influence this age-related reduction of ASD
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symptoms in ADHD subjects. Therefore, the neural correlates of
this finding remain unknown. Analyses of regional brain volume
changes, as well as changes in WM indices of diffusion will be
undertaken in a future study and may be able to shed light on this
point. One possibility is that while total WM or GM volume may
not have an influence on age-related changes in ASD symptoms,
subtle regional changes in GM and WM structure changes may lie
hidden beneath the global analysis. Structural and functional MRI
studies have consistently found the caudate nucleus to be altered in
ASD and to be associated with dysfunctions in multiple domains
related to ASD, such as repetitive and stereotyped behaviour [72],
reward processing [73–75] and executive function [73]. Caudate
damage has also been related to reduced cognitive flexibility and
perseverative behaviour in a range of species, including monkeys
[76], birds [77], rats [78] and cats [79]. Clearly, developmental
changes play a crucial role in influencing the trajectories of both
disorders. Significant age-related improvements have been noted
in restricted and repetitive behaviours [80] and also in overall
ASD symptom counts [81]. The significant reduction of ASD
scores may be related to a reduction of local short-range circuitry
together with a strengthening of long-range connectivity that is
seen in adolescent brain development [82]. Normal development
is associated with marked changes in WM tracts, with myelination
increasing throughout childhood and adolescence [83]. Increasing
myelination of fronto-striatal connections during adolescence and
early adulthood facilitates top-down executive control of behav-
iour [84]. Indices of WM integrity such as fractional anisotropy
have been found to normalise in ADHD subjects as they progress
to adolescence and adulthood [85]. Thus, the apparent improve-
ments in autism symptoms with age as seen in the current study
may be associated with improvements in WM integrity. Social
adaptation may contribute to a reduction of ASD symptoms with
age. Initial studies have also indicated that cognitive behavioural
therapy (CBT), when adapted to the special needs of patients with
ASD, can offer an effective treatment modality [86], [87,88].
Although there are no pharmacological treatments that specifically
target the deficits of ASD, some studies have noted improvement
in behavioural symptoms with risperidone [89], while reductions
in repetitive behaviours have been found following treatment with
oxytocin [90]. Within the current cohort, individuals with low IQ
(,70) were excluded, thus an IQ within a normal range may also
facilitate compensation or adaptive mechanisms that help ADHD
individuals to reduce the overt expression of ASD symptoms.
The current study should be viewed in the context of some
limitations. The results are cross-sectional. Future longitudinal
studies of MRI-measured developmental trajectories are needed
for assessing the impact of age on developing brain structures. The
results are also based on global volumetric changes and do not
identify specific regional increases or decreases in WM or GM
volume. Studies are underway which will assess the current data
set in terms of specific regional WM and GM volumetric
differences that occur with elevated ASD symptoms. The fact
that clinical ASD cases were not included in the cohort is an
additional limitation of the study. While the ASD score derived
from the aggregate of four sub-scales of the CSBQ questionnaire
(social interest, social understanding, stereotypy and resistance to
change) has been successfully used to probe ASD symptoms in the
past [47,54], caution is needed when interpreting this score as not
all social deficits present in ADHD overlap with ASD symptoms
[91]. The fact that participants were of European (Caucasian)
descent is another limitation, and indicates that results may not be
readily generalisable to other communities or ethnicities.
Figure 5. ADHD subjects with low ASD scores have significantly lower total intracranial volume than control subjects (p,0.05).
ADHD: low ASD is defined as a participant with ADHD and an ASD score of 20 or less. ADHD: high ASD is defined as a participant with ADHD and an
ASD score greater than 20.
doi:10.1371/journal.pone.0101130.g005
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Overall, the current results highlight a specific volumetric profile
that is associated with elevated ASD symptoms. This is the first
study in a large cohort that robustly accounts for the phenotypic
overlap between the ADHD and ASD. Equivocal findings in
previous volumetric studies of ADHD and ASD may be due to the
fact that issues of comorbidity have generally been ignored in studies
to date. Assessing the range of volumetric profiles associated with
ADHD coupled with mild ASD symptoms, through to ADHD
coupled with severe ASD symptoms, will help to develop a more
nuanced understanding of the pathophysiology associated with the
continuous distribution and overlap of these two disorders.
Supporting Information
Table S1 Medication Information.
(DOCX)
Table S2 Distribution of Scanning over Two Sites.
(DOCX)
Table S3 Correlation between ASD score and ADHD
symptom levels.
(DOCX)
Table S4 Final, generalised mixed-effect model for ASD
score modelled against Grey Matter Residual and White
Matter Volumes.
(DOCX)
Table S5 Final, generalised mixed-effect model for ASD
score modelled against Grey Matter and White Matter
Volumes using only participants with an ASD score of 20
or higher.
(DOCX)
Diagnostic Algorithm S1 Diagnostic algorithm for
ADHD in the NeuroIMAGE sample.
(DOCX)
Questionnaire Items S1 Children’s Social and Behav-
ioural Questionnaire (CSBQ) Summary.
(DOCX)
Author Contributions
Conceived and designed the experiments: LOD EVD JKB. Performed the
experiments: LOD. Analyzed the data: LOD CT MPZ. Contributed
reagents/materials/analysis tools: JKB CT MPZ. Wrote the paper: LOD.
Edited the manuscript and contributed conceptual improvements: CUG JB
MPZ BF JO DH PH CAH NR JKB.
References
1. Rommelse NNJ, Franke B, Geurts HM, Hartman CA, Buitelaar JK (2010)
Shared heritability of attention-deficit/hyperactivity disorder and autism
spectrum disorder. Eur Child Adolesc Psychiatry 19: 281–295. doi:10.1007/
s00787-010-0092-x.
2. Ronald A, Simonoff E, Kuntsi J, Asherson P, Plomin R (2008) Evidence for
overlapping genetic influences on autistic and ADHD behaviours in a
community twin sample. J Child Psychol Psychiatry 49: 535–542.
doi:10.1111/j.1469-7610.2007.01857.x.
3. Association AP (2000) Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition: DSM-IV-TR. American Psychiatric Pub. 996 p.
4. Ames CS, White SJ (2011) Are ADHD traits dissociable from the autistic profile?
Links between cognition and behaviour. J Autism Dev Disord 41: 357–363.
doi:10.1007/s10803-010-1049-0.
5. Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, et al. (2006) Comorbid
psychiatric disorders in children with autism: interview development and rates of
disorders. J Autism Dev Disord 36: 849–861. doi:10.1007/s10803-006-0123-0.
6. Van Steijn DJ, Richards JS, Oerlemans AM, de Ruiter SW, van Aken MAG, et
al. (2012) The co-occurrence of autism spectrum disorder and attention-deficit/
hyperactivity disorder symptoms in parents of children with ASD or ASD with
ADHD. J Child Psychol Psychiatry 53: 954–963. doi:10.1111/j.1469-
7610.2012.02556.x.
7. Corbett BA, Constantine LJ, Hendren R, Rocke D, Ozonoff S (2009) Examining
executive functioning in children with autism spectrum disorder, attention deficit
hyperactivity disorder and typical development. Psychiatry Res 166: 210–222.
doi:10.1016/j.psychres.2008.02.005.
8. Fine JG, Semrud-Clikeman M, Butcher B, Walkowiak J (2008) Brief report:
attention effect on a measure of social perception. J Autism Dev Disord 38:
1797–1802. doi:10.1007/s10803-008-0570-x.
9. Booth R, Happe´ F (2010) ‘‘Hunting with a knife and … fork’’: examining central
coherence in autism, attention deficit/hyperactivity disorder, and typical
development with a linguistic task. J Exp Child Psychol 107: 377–393.
doi:10.1016/j.jecp.2010.06.003.
10. Chabernaud C, Mennes M, Kelly C, Nooner K, Di Martino A, et al. (2012)
Dimensional brain-behavior relationships in children with attention-deficit/
hyperactivity disorder. Biol Psychiatry 71: 434–442. doi:10.1016/j.biop-
sych.2011.08.013.
11. Shaw P, Gilliam M, Liverpool M, Weddle C, Malek M, et al. (2011) Cortical
development in typically developing children with symptoms of hyperactivity
and impulsivity: support for a dimensional view of attention deficit hyperactivity
disorder. Am J Psychiatry 168: 143–151. doi:10.1176/appi.ajp.2010.10030385.
12. Castellanos FX, Tannock R (2002) Neuroscience of attention-deficit/hyperac-
tivity disorder: the search for endophenotypes. Nat Rev Neurosci 3: 617–628.
doi:10.1038/nrn896.
13. Reiersen AM, Constantino JN, Volk HE, Todd RD (2007) Autistic traits in a
population-based ADHD twin sample. J Child Psychol Psychiatry 48: 464–472.
doi:10.1111/j.1469-7610.2006.01720.x.
14. Geurts HM, Ridderinkhof KR, Scholte HS (2013) The relationship between
grey-matter and ASD and ADHD traits in typical adults. J Autism Dev Disord
43: 1630–1641. doi:10.1007/s10803-012-1708-4.
15. Valera EM, Faraone SV, Murray KE, Seidman LJ (2007) Meta-analysis of
structural imaging findings in attention-deficit/hyperactivity disorder. Biol
Psychiatry 61: 1361–1369. doi:10.1016/j.biopsych.2006.06.011.
16. Frodl T, Skokauskas N (2012) Meta-analysis of structural MRI studies in
children and adults with attention deficit hyperactivity disorder indicates
treatment effects. Acta Psychiatr Scand 125: 114–126. doi:10.1111/j.1600-
0447.2011.01786.x.
17. Nakao T, Radua J, Rubia K, Mataix-Cols D (2011) Gray matter volume
abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age
and stimulant medication. Am J Psychiatry 168: 1154–1163. doi:10.1176/
appi.ajp.2011.11020281.
18. Seidman LJ, Biederman J, Liang L, Valera EM, Monuteaux MC, et al. (2011)
Gray matter alterations in adults with attention-deficit/hyperactivity disorder
identified by voxel based morphometry. Biol Psychiatry 69: 857–866.
doi:10.1016/j.biopsych.2010.09.053.
19. Carmona S, Vilarroya O, Bielsa A, Tre`mols V, Soliva JC, et al. (2005) Global
and regional gray matter reductions in ADHD: a voxel-based morphometric
study. Neurosci Lett 389: 88–93. doi:10.1016/j.neulet.2005.07.020.
20. Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann WE (2002)
Smaller prefrontal and premotor volumes in boys with attention-deficit/
hyperactivity disorder. Biol Psychiatry 52: 785–794.
21. Shaw P, Gogtay N, Rapoport J (2010) Childhood psychiatric disorders as
anomalies in neurodevelopmental trajectories. Hum Brain Mapp 31: 917–925.
doi:10.1002/hbm.21028.
22. Courchesne E, Carper R, Akshoomoff N (2003) Evidence of brain overgrowth in
the first year of life in autism. JAMA 290: 337–344. doi:10.1001/
jama.290.3.337.
23. Redcay E, Courchesne E (2005) When is the brain enlarged in autism? A meta-
analysis of all brain size reports. Biol Psychiatry 58: 1–9. doi:10.1016/
j.biopsych.2005.03.026.
24. Freitag CM, Luders E, Hulst HE, Narr KL, Thompson PM, et al. (2009) Total
brain volume and corpus callosum size in medication-naı¨ve adolescents and
young adults with autism spectrum disorder. Biol Psychiatry 66: 316–319.
doi:10.1016/j.biopsych.2009.03.011.
25. Herbert MR, Ziegler DA, Deutsch CK, O’Brien LM, Lange N, et al. (2003)
Dissociations of cerebral cortex, subcortical and cerebral white matter volumes
in autistic boys. Brain 126: 1182–1192.
26. Herbert MR (2005) Large brains in autism: the challenge of pervasive
abnormality. Neuroscientist 11: 417–440. doi:10.1177/0091270005278866.
27. Herbert MR, Ziegler DA, Makris N, Filipek PA, Kemper TL, et al. (2004)
Localization of white matter volume increase in autism and developmental
language disorder. Ann Neurol 55: 530–540. doi:10.1002/ana.20032.
28. Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, et al. (2001)
Unusual brain growth patterns in early life in patients with autistic disorder: an
MRI study. Neurology 57: 245–254.
29. Chung MK, Dalton KM, Alexander AL, Davidson RJ (2004) Less white matter
concentration in autism: 2D voxel-based morphometry. Neuroimage 23: 242–
251. doi:10.1016/j.neuroimage.2004.04.037.
30. Waiter GD, Williams JHG, Murray AD, Gilchrist A, Perrett DI, et al. (2005)
Structural white matter deficits in high-functioning individuals with autistic
ASD Spectrum Traits in ADHD
PLOS ONE | www.plosone.org 11 June 2014 | Volume 9 | Issue 6 | e101130
spectrum disorder: a voxel-based investigation. Neuroimage 24: 455–461.
doi:10.1016/j.neuroimage.2004.08.049.
31. Radua J, Via E, Catani M, Mataix-Cols D (2011) Voxel-based meta-analysis of
regional white-matter volume differences in autism spectrum disorder versus
hea l thy control s . Psychol Med 41: 1539–1550. doi :10.1017/
S0033291710002187.
32. Vaccarino FM, Grigorenko EL, Smith KM, Stevens HE (2009) Regulation of
cerebral cortical size and neuron number by fibroblast growth factors:
implications for autism. J Autism Dev Disord 39: 511–520. doi:10.1007/
s10803-008-0653-8.
33. Via E, Radua J, Cardoner N, Happe´ F, Mataix-Cols D (2011) Meta-analysis of
gray matter abnormalities in autism spectrum disorder: should Asperger disorder
be subsumed under a broader umbrella of autistic spectrum disorder? Arch Gen
Psychiatry 68: 409–418. doi:10.1001/archgenpsychiatry.2011.27.
34. Nickl-Jockschat T, Habel U, Michel TM, Manning J, Laird AR, et al. (2012)
Brain structure anomalies in autism spectrum disorder–a meta-analysis of VBM
studies using anatomic likelihood estimation. Hum Brain Mapp 33: 1470–1489.
doi:10.1002/hbm.21299.
35. Helt M, Kelley E, Kinsbourne M, Pandey J, Boorstein H, et al. (2008) Can
children with autism recover? If so, how? Neuropsychol Rev 18: 339–366.
doi:10.1007/s11065-008-9075-9.
36. Hesslinger B, Tebartz van Elst L, Thiel T, Haegele K, Hennig J, et al. (2002)
Frontoorbital volume reductions in adult patients with attention deficit
hyperactivity disorder. Neurosci Lett 328: 319–321.
37. Amaral DG, Schumann CM, Nordahl CW (2008) Neuroanatomy of autism.
Trends Neurosci 31: 137–145. doi:10.1016/j.tins.2007.12.005.
38. Piven J, Arndt S, Bailey J, Andreasen N (1996) Regional brain enlargement in
autism: a magnetic resonance imaging study. J Am Acad Child Adolesc
Psychiatry 35: 530–536. doi:10.1097/00004583-199604000-00020.
39. Brieber S, Neufang S, Bruning N, Kamp-Becker I, Remschmidt H, et al. (2007)
Structural brain abnormalities in adolescents with autism spectrum disorder and
patients with attention deficit/hyperactivity disorder. J Child Psychol Psychiatry
48: 1251–1258. doi:10.1111/j.1469-7610.2007.01799.x.
40. Nijmeijer JS, Hoekstra PJ, Minderaa RB, Buitelaar JK, Altink ME, et al. (2009)
PDD symptoms in ADHD, an independent familial trait? J Abnorm Child
Psychol 37: 443–453. doi:10.1007/s10802-008-9282-0.
41. Mu¨ller UC, Asherson P, Banaschewski T, Buitelaar JK, Ebstein RP, et al. (2011)
The impact of study design and diagnostic approach in a large multi-centre
ADHD study. Part 1: ADHD symptom patterns. BMC Psychiatry 11: 54.
doi:10.1186/1471-244X-11-54.
42. Mu¨ller UC, Asherson P, Banaschewski T, Buitelaar JK, Ebstein RP, et al. (2011)
The impact of study design and diagnostic approach in a large multi-centre
ADHD study: Part 2: Dimensional measures of psychopathology and
intelligence. BMC Psychiatry 11: 55. doi:10.1186/1471-244X-11-55.
43. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, et al. (1997) Schedule for
Affective Disorders and Schizophrenia for School-Age Children-Present and
Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad
Child Adolesc Psychiatry 36: 980–988. doi:10.1097/00004583-199707000-
00021.
44. Hartman CA, Luteijn E, Serra M, Minderaa R (2006) Refinement of the
Children’s Social Behavior Questionnaire (CSBQ): an instrument that describes
the diverse problems seen in milder forms of PDD. J Autism Dev Disord 36:
325–342. doi:10.1007/s10803-005-0072-z.
45. Luteijn EF, Serra M, Jackson S, Steenhuis MP, Althaus M, et al. (2000) How
unspecified are disorders of children with a pervasive developmental disorder not
otherwise specified? A study of social problems in children with PDD-NOS and
ADHD. Eur Child Adolesc Psychiatry 9: 168–179.
46. Nijmeijer JS, Arias-Va´squez A, Rommelse NNJ, Altink ME, Buschgens CJM, et
al. (2014) Quantitative Linkage for Autism Spectrum Disorders Symptoms in
Attention-Deficit/Hyperactivity Disorder: Significant Locus on Chromosome
7q11. J Autism Dev Disord. doi:10.1007/s10803-014-2039-4.
47. Jaspers M, de Winter AF, Buitelaar JK, Verhulst FC, Reijneveld SA, et al. (2012)
Early Childhood Assessments of Community Pediatric Professionals Predict
Autism Spectrum and Attention Deficit Hyperactivity Problems. Journal of
abnormal child psychology. doi:10.1007/s10802-012-9653-4.
48. Greaves-Lord K, Eussen MLJM, Verhulst FC, Minderaa RB, Mandy W, et al.
(2013) Empirically based phenotypic profiles of children with pervasive
developmental disorders: interpretation in the light of the DSM-5. J Autism
Dev Disord 43: 1784–1797. doi:10.1007/s10803-012-1724-4.
49. Geluk CAML, Jansen LMC, Vermeiren R, Doreleijers TAH, van Domburgh L,
et al. (2012) Autistic symptoms in childhood arrestees: longitudinal association
with delinquent behavior. J Child Psychol Psychiatry 53: 160–167. doi:10.1111/
j.1469-7610.2011.02456.x.
50. Rommelse NNJ, Geurts HM, Franke B, Buitelaar JK, Hartman CA (2011) A
review on cognitive and brain endophenotypes that may be common in autism
spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the
search for pleiotropic genes. Neurosci Biobehav Rev 35: 1363–1396.
doi:10.1016/j.neubiorev.2011.02.015.
51. Geurts HM, Luman M, van Meel CS (2008) What’s in a game: the effect of
social motivation on interference control in boys with ADHD and autism
spectrum disorders. J Child Psychol Psychiatry 49: 848–857. doi:10.1111/
j.1469-7610.2008.01916.x.
52. Krug DA, Arick J, Almond P (1980) Behavior checklist for identifying severely
handicapped individuals with high levels of autistic behavior. J Child Psychol
Psychiatry 21: 221–229.
53. De Bildt A, Mulder EJ, Hoekstra PJ, van Lang NDJ, Minderaa RB, et al. (2009)
Validity of the Children’s Social Behavior Questionnaire (CSBQ) in children
with intellectual disability: comparing the CSBQ with ADI-R, ADOS, and
clinical DSM-IV-TR classification. J Autism Dev Disord 39: 1464–1470.
doi:10.1007/s10803-009-0764-x.
54. ’t Hart-Kerkhoffs LA, Jansen LM, Doreleijers TA, Vermeiren R, Minderaa RB,
et al. (2009) Autism spectrum disorder symptoms in juvenile suspects of sex
offenses. J Clin Psychiatry 70: 266–272.
55. Ashburner J, Friston KJ (2005) Unified segmentation. Neuroimage 26: 839–851.
doi:10.1016/j.neuroimage.2005.02.018.
56. R Development Core Team (2010) R: A Language and Environment for
Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
Available: http://www.R-project.org.
57. Bates D, Maechler M, Bolker B (n.d.) lme4: Linear Mixed-Effects Models Using
S4 Classes. Available: http://CRAN.R-project.org/package = lme4.
58. Anderson D.R, Burnham K.P. (2002) Model selection and multimodel
inference: a practical information-theoretic approach. 2nd Edition. New York,
New York, USA: Springer-Verlag. 488 p.
59. Akaike H (1979) A Bayesian extension of the minimum AIC procedure of
autoregressive model fitting. Biometrika 66: 237–242. doi:10.1093/biomet/
66.2.237.
60. Crawley MJ (2007) The R Book. Available: http://onlinelibrary.wiley.com/
book/10.1002/9780470515075. Accessed 31 August 2012.
61. O’Dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, et al. (2012)
Reduced Hippocampal Volume in Healthy Young ApoE4 Carriers: An MRI
Study. PLoS ONE 7: e48895. doi:10.1371/journal.pone.0048895.
62. Van der Meer JMJ, Oerlemans AM, van Steijn DJ, Lappenschaar MGA, de
Sonneville LMJ, et al. (2012) Are autism spectrum disorder and attention-
deficit/hyperactivity disorder different manifestations of one overarching
disorder? Cognitive and symptom evidence from a clinical and population-
based sample. J Am Acad Child Adolesc Psychiatry 51: 1160–1172.e3.
doi:10.1016/j.jaac.2012.08.024.
63. Mulligan A, Anney RJL, O’Regan M, Chen W, Butler L, et al. (2009) Autism
symptoms in Attention-Deficit/Hyperactivity Disorder: a familial trait which
correlates with conduct, oppositional defiant, language and motor disorders.
J Autism Dev Disord 39: 197–209. doi:10.1007/s10803-008-0621-3.
64. Courchesne E, Campbell K, Solso S (2011) Brain growth across the life span in
autism: Age-specific changes in anatomical pathology. Brain Research 1380:
138–145. doi:10.1016/j.brainres.2010.09.101.
65. Hynd GW, Semrud-Clikeman M, Lorys AR, Novey ES, Eliopulos D (1990)
Brain morphology in developmental dyslexia and attention deficit disorder/
hyperactivity. Arch Neurol 47: 919–926.
66. Lyoo IK, Noam GG, Lee CK, Lee HK, Kennedy BP, et al. (1996) The corpus
callosum and lateral ventricles in children with attention-deficit hyperactivity
disorder: a brain magnetic resonance imaging study. Biol Psychiatry 40: 1060–
1063.
67. Bussing R, Grudnik J, Mason D, Wasiak M, Leonard C (2002) ADHD and
conduct disorder: an MRI study in a community sample. World J Biol Psychiatry
3: 216–220.
68. Durston S, Hulshoff Pol HE, Schnack HG, Buitelaar JK, Steenhuis MP, et al.
(2004) Magnetic resonance imaging of boys with attention-deficit/hyperactivity
disorder and their unaffected siblings. J Am Acad Child Adolesc Psychiatry 43:
332–340.
69. Happe´ F, Booth R, Charlton R, Hughes C (2006) Executive function deficits in
autism spectrum disorders and attention-deficit/hyperactivity disorder: examin-
ing profiles across domains and ages. Brain Cogn 61: 25–39. doi:10.1016/
j.bandc.2006.03.004.
70. Howlin P, Mawhood L, Rutter M (2000) Autism and developmental receptive
language disorder–a follow-up comparison in early adult life. II: Social,
behavioural, and psychiatric outcomes. J Child Psychol Psychiatry 41: 561–578.
71. Seltzer MM, Shattuck P, Abbeduto L, Greenberg JS (2004) Trajectory of
development in adolescents and adults with autism. Mental Retardation and
Developmental Disabilities Research Reviews 10: 234–247. doi:10.1002/
mrdd.20038.
72. Langen M, Schnack HG, Nederveen H, Bos D, Lahuis BE, et al. (2009) Changes
in the developmental trajectories of striatum in autism. Biol Psychiatry 66: 327–
333. doi:10.1016/j.biopsych.2009.03.017.
73. Grahn JA, Parkinson JA, Owen AM (2009) The role of the basal ganglia in
learning and memory: Neuropsychological studies. Behavioural Brain Research
199: 53–60. doi:10.1016/j.bbr.2008.11.020.
74. Schultz W, Tremblay L, Hollerman JR (2000) Reward processing in primate
orbitofrontal cortex and basal ganglia. Cereb Cortex 10: 272–284.
75. Heimer L (2003) A new anatomical framework for neuropsychiatric disorders
and drug abuse. Am J Psychiatry 160: 1726–1739.
76. Divac I, Rosvold HE, Szwarcbart MK (1967) Behavioral effects of selective
ablation of the caudate nucleus. J Comp Physiol Psychol 63: 184–190.
77. Stettner LJ, Schultz WJ (1967) Brain lesions in birds: effects on discrimination
acquisition and reversal. Science 155: 1689–1692.
78. Kirkby RJ (1969) Caudate nucleus lesions and perseverative behavior.
Physiology & Behavior 4: 451–454. doi:10.1016/0031-9384(69)90135-8.
ASD Spectrum Traits in ADHD
PLOS ONE | www.plosone.org 12 June 2014 | Volume 9 | Issue 6 | e101130
79. Thompson RL (1959) Effects of lesions in the caudate nuclei and dorsofrontal
cortex on conditioned avoidance behavior in cats. J Comp Physiol Psychol 52:
650–659.
80. Esbensen AJ, Seltzer MM, Lam KSL, Bodfish JW (2009) Age-related differences
in restricted repetitive behaviors in autism spectrum disorders. J Autism Dev
Disord 39: 57–66. doi:10.1007/s10803-008-0599-x.
81. Taylor JL, Seltzer MM (2010) Changes in the autism behavioral phenotype
during the transition to adulthood. J Autism Dev Disord 40: 1431–1446.
doi:10.1007/s10803-010-1005-z.
82. Dosenbach NUF, Nardos B, Cohen AL, Fair DA, Power JD, et al. (2010)
Prediction of individual brain maturity using fMRI. Science 329: 1358–1361.
doi:10.1126/science.1194144.
83. Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, et al.
(1994) A quantitative magnetic resonance imaging study of changes in brain
morphology from infancy to late adulthood. Arch Neurol 51: 874–887.
84. Asato MR, Terwilliger R, Woo J, Luna B (2010) White matter development in
adolescence: a DTI study. Cereb Cortex 20: 2122–2131. doi:10.1093/cercor/
bhp282.
85. Kleinhans NM, Pauley G, Richards T, Neuhaus E, Martin N, et al. (2012) Age-
related abnormalities in white matter microstructure in autism spectrum
disorders. Brain Res 1479: 1–16. doi:10.1016/j.brainres.2012.07.056.
86. Dawson G (2008) Early behavioral intervention, brain plasticity, and the
prevention of autism spectrum disorder. Development and Psychopathology 20:
775–803. doi:10.1017/S0954579408000370.
87. Scarpa A, Reyes NM (2011) Improving Emotion Regulation with CBT in
Young Children with High Functioning Autism Spectrum Disorders: A Pilot
Study. Behavioural and Cognitive Psychotherapy 39: 495–500. doi:10.1017/
S1352465811000063.
88. Sze KM, Wood JJ (2008) Enhancing CBT for the Treatment of Autism
Spectrum Disorders and Concurrent Anxiety. Behavioural and Cognitive
Psychotherapy 36. Available: http://www.journals.cambridge.org/abstract_
S1352465808004384. Accessed 10 March 2014.
89. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, et al. (2004) Risperidone in the
Treatment of Disruptive Behavioral Symptoms in Children With Autistic and
Other Pervasive Developmental Disorders. Pediatrics 114: e634–e641.
doi:10.1542/peds.2003-0264-F.
90. Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, et al. (2003)
Oxytocin infusion reduces repetitive behaviors in adults with autistic and
Asperger’s disorders. Neuropsychopharmacology 28: 193–198. doi:10.1038/
sj.npp.1300021.
91. Matson JL, Nebel-Schwalm MS (2007) Comorbid psychopathology with autism
spectrum disorder in children: an overview. Res Dev Disabil 28: 341–352.
doi:10.1016/j.ridd.2005.12.004.
ASD Spectrum Traits in ADHD
PLOS ONE | www.plosone.org 13 June 2014 | Volume 9 | Issue 6 | e101130
